3,133 Shares in Biogen Inc. $BIIB Bought by Phoenix Financial Ltd.

Phoenix Financial Ltd. acquired a new position in shares of Biogen Inc. (NASDAQ:BIIB) in the 4th quarter, HoldingsChannel reports. The institutional investor acquired 3,133 shares of the biotechnology company’s stock, valued at approximately $551,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Convergence Investment Partners LLC acquired a new position in Biogen during the third quarter worth $1,342,000. Caprock Group LLC acquired a new position in Biogen during the third quarter worth $742,000. Leuthold Group LLC acquired a new position in Biogen during the third quarter worth $3,294,000. Generali Investments Management Co LLC increased its position in Biogen by 408.2% during the third quarter. Generali Investments Management Co LLC now owns 9,970 shares of the biotechnology company’s stock worth $1,397,000 after buying an additional 8,008 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in Biogen by 9.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 67,010 shares of the biotechnology company’s stock worth $9,387,000 after buying an additional 5,987 shares during the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Biogen Trading Up 0.8%

Shares of BIIB opened at $192.95 on Friday. Biogen Inc. has a 12-month low of $121.05 and a 12-month high of $205.97. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34. The firm has a market capitalization of $28.49 billion, a price-to-earnings ratio of 20.70, a P/E/G ratio of 1.70 and a beta of 0.19. The stock’s 50-day moving average price is $185.21 and its 200 day moving average price is $179.33.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The firm had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same period in the previous year, the company posted $3.02 earnings per share. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, research analysts predict that Biogen Inc. will post 14.21 earnings per share for the current year.

Analyst Upgrades and Downgrades

BIIB has been the topic of several analyst reports. Oppenheimer increased their target price on shares of Biogen from $275.00 to $300.00 and gave the stock an “outperform” rating in a research report on Thursday. Wedbush raised their price target on Biogen from $191.00 to $196.00 and gave the company a “neutral” rating in a research report on Thursday, April 30th. Freedom Capital raised Biogen from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 1st. Mizuho raised their price target on Biogen from $207.00 to $236.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. Finally, UBS Group raised Biogen from a “neutral” rating to a “buy” rating and raised their price target for the company from $185.00 to $225.00 in a research report on Wednesday, April 22nd. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Biogen currently has a consensus rating of “Moderate Buy” and an average target price of $215.62.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen said its Phase 2 CELIA study of diranersen (BIIB080), a tau-targeting Alzheimer’s drug, showed robust reductions in tau pathology and signals of slowed cognitive decline, prompting the company to advance the program into late-stage development. Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
• Positive Sentiment: Goldman Sachs reiterated a Buy rating and lifted its price target to $250, while Oppenheimer raised its target to $300 and Evercore initiated coverage with an Outperform rating, reinforcing optimism around Biogen’s valuation and pipeline. Goldman’s Richter Reiterates Buy on Biogen as Leqembi Outperforms and Price Target Rises from $238 to $250 Oppenheimer raises Biogen price target to $300 from $275, maintains Outperform rating
• Positive Sentiment: Biogen completed its $5.3 billion acquisition of Apellis Pharmaceuticals, adding commercial products SYFOVRE and EMPAVELI and potentially improving near-term growth prospects. Biogen Completes Acquisition of Apellis Pharmaceuticals
• Neutral Sentiment: Some analysts remain cautious, saying mixed Alzheimer’s data and pipeline uncertainty still create a balanced risk/reward profile despite the recent rally. Biogen: Hold Rating Reiterated as Pipeline Concerns Offset Leqembi Growth; $196 Price Target Maintained
• Negative Sentiment: The CELIA study missed its primary endpoint, and a law firm has already announced an investigation into possible securities-law issues tied to the stock’s move after the data release, which could add headline risk. Investigation Alert: Biogen Inc. (BIIB) Under Scrutiny – Contact Levi & Korsinsky for Details

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.